RE: Testimony before the United States Senate Committee on Health20 Mar 2021 09:47
Great find Mikekep thanks
Just to reiterate
copy and paste
"ACTIV-2, which is focused on outpatients, has since been expanded to evaluate a
combination monoclonal antibody therapy, BRII-196 and BRII-198, as well as three
6 investigational therapeutics: SNG001, an inhalable beta interferon; AZD7442, an investigational
long-acting antibody combination; and camostat mesilate, an orally administered molecule that
may block SARS-CoV-2 from entering cells. "